| Literature DB >> 26130273 |
R Bajo1, S Pusil1, M E López1, L Canuet1, E Pereda2, D Osipova3, F Maestú1, E Pekkonen4.
Abstract
Scopolamine administration may be considered as a psychopharmacological model of Alzheimer's disease (AD). Here, we studied a group of healthy elderly under scopolamine to test whether it elicits similar changes in brain connectivity as those observed in AD, thereby verifying a possible model of AD impairment. We did it by testing healthy elderly subjects in two experimental conditions: glycopyrrolate (placebo) and scopolamine administration. We then analyzed magnetoencephalographic (MEG) data corresponding to both conditions in resting-state with eyes closed. This analysis was performed in source space by combining a nonlinear frequency band-specific measure of functional connectivity (phase locking value, PLV) with network analysis methods. Under scopolamine, functional connectivity between several brain areas was significantly reduced as compared to placebo, in most frequency bands analyzed. Besides, regarding the two complex network indices studied (clustering and shortest path length), clustering significantly decreased in the alpha band while shortest path length significantly increased also in alpha band both after scopolamine administration. Overall our findings indicate that both PLV and graph analysis are suitable tools to measure brain connectivity changes induced by scopolamine, which causes alterations in brain connectivity apparently similar to those reported in AD.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26130273 PMCID: PMC4486953 DOI: 10.1038/srep09748
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Significant differences in PLV between the Glycopyrrolate (placebo) and the scopolamine conditions for different frequency bands (at the p<0.005 level). In the delta band (top left) the synchronization between left parahippocampal and right occipital interior cortex increases under the scopolamine. On the contrary in alpha (top right), beta (bottom left) and gamma bands (bottom right) the PLV decreases between different brain regions under scopolamine.
Figure 2(a) Network parameters (C and L mean values) for each frequency band and condition (placebo and Scopolamine); (b) Statistically significant differences (p values) for C and L, when comparing both conditions (Glycopyrrolate (placebo) vs. Scopolamine) for each frequency band; (c) In alpha band, C shows a significant reduction under scopolamine as compared to placebo, while L shows a significant increased.